Literature DB >> 20660270

Cholinergic modulation of locomotion and striatal dopamine release is mediated by alpha6alpha4* nicotinic acetylcholine receptors.

Ryan M Drenan1, Sharon R Grady, Andrew D Steele, Sheri McKinney, Natalie E Patzlaff, J Michael McIntosh, Michael J Marks, Julie M Miwa, Henry A Lester.   

Abstract

Dopamine (DA) release in striatum is governed by firing rates of midbrain DA neurons, striatal cholinergic tone, and nicotinic ACh receptors (nAChRs) on DA presynaptic terminals. DA neurons selectively express alpha6* nAChRs, which show high ACh and nicotine sensitivity. To help identify nAChR subtypes that control DA transmission, we studied transgenic mice expressing hypersensitive alpha6(L9'S)* receptors. alpha6(L9'S) mice are hyperactive, travel greater distance, exhibit increased ambulatory behaviors such as walking, turning, and rearing, and show decreased pausing, hanging, drinking, and grooming. These effects were mediated by alpha6alpha4* pentamers, as alpha6(L9'S) mice lacking alpha4 subunits displayed essentially normal behavior. In alpha6(L9'S) mice, receptor numbers are normal, but loss of alpha4 subunits leads to fewer and less sensitive alpha6* receptors. Gain-of-function nicotine-stimulated DA release from striatal synaptosomes requires alpha4 subunits, implicating alpha6alpha4beta2* nAChRs in alpha6(L9'S) mouse behaviors. In brain slices, we applied electrochemical measurements to study control of DA release by alpha6(L9'S) nAChRs. Burst stimulation of DA fibers elicited increased DA release relative to single action potentials selectively in alpha6(L9'S), but not WT or alpha4KO/alpha6(L9'S), mice. Thus, increased nAChR activity, like decreased activity, leads to enhanced extracellular DA release during phasic firing. Bursts may directly enhance DA release from alpha6(L9'S) presynaptic terminals, as there was no difference in striatal DA receptor numbers or DA transporter levels or function in vitro. These results implicate alpha6alpha4beta2* nAChRs in cholinergic control of DA transmission, and strongly suggest that these receptors are candidate drug targets for disorders involving the DA system.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20660270      PMCID: PMC3390922          DOI: 10.1523/JNEUROSCI.2056-10.2010

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  59 in total

1.  Chronic nicotine cell specifically upregulates functional alpha 4* nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path.

Authors:  Raad Nashmi; Cheng Xiao; Purnima Deshpande; Sheri McKinney; Sharon R Grady; Paul Whiteaker; Qi Huang; Tristan McClure-Begley; Jon M Lindstrom; Cesar Labarca; Allan C Collins; Michael J Marks; Henry A Lester
Journal:  J Neurosci       Date:  2007-08-01       Impact factor: 6.167

2.  Nicotinic alpha5 subunit deletion locally reduces high-affinity agonist activation without altering nicotinic receptor numbers.

Authors:  Robert W B Brown; Allan C Collins; Jon M Lindstrom; Paul Whiteaker
Journal:  J Neurochem       Date:  2007-06-15       Impact factor: 5.372

3.  Axon initial segment Kv1 channels control axonal action potential waveform and synaptic efficacy.

Authors:  Maarten H P Kole; Johannes J Letzkus; Greg J Stuart
Journal:  Neuron       Date:  2007-08-16       Impact factor: 17.173

4.  The power of automated high-resolution behavior analysis revealed by its application to mouse models of Huntington's and prion diseases.

Authors:  Andrew D Steele; Walker S Jackson; Oliver D King; Susan Lindquist
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-29       Impact factor: 11.205

5.  Expression of nigrostriatal alpha 6-containing nicotinic acetylcholine receptors is selectively reduced, but not eliminated, by beta 3 subunit gene deletion.

Authors:  Cecilia Gotti; Milena Moretti; Francesco Clementi; Loredana Riganti; J Michael McIntosh; Allan C Collins; Michael J Marks; Paul Whiteaker
Journal:  Mol Pharmacol       Date:  2005-03-04       Impact factor: 4.436

Review 6.  Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex.

Authors:  Satoshi Ikemoto
Journal:  Brain Res Rev       Date:  2007-05-17

7.  Frequency-dependent modulation of dopamine release by nicotine.

Authors:  Hui Zhang; David Sulzer
Journal:  Nat Neurosci       Date:  2004-05-16       Impact factor: 24.884

Review 8.  Nicotine and Parkinson's disease: implications for therapy.

Authors:  Maryka Quik; Kathryn O'Leary; Caroline M Tanner
Journal:  Mov Disord       Date:  2008-09-15       Impact factor: 10.338

9.  Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice.

Authors:  Outi Salminen; Karen L Murphy; J Michael McIntosh; John Drago; Michael J Marks; Allan C Collins; Sharon R Grady
Journal:  Mol Pharmacol       Date:  2004-06       Impact factor: 4.436

10.  Dopamine signaling differences in the nucleus accumbens and dorsal striatum exploited by nicotine.

Authors:  Tianxiang Zhang; Lifen Zhang; Yong Liang; Athanassios G Siapas; Fu-Ming Zhou; John A Dani
Journal:  J Neurosci       Date:  2009-04-01       Impact factor: 6.167

View more
  77 in total

1.  Nicotinic cholinergic mechanisms causing elevated dopamine release and abnormal locomotor behavior.

Authors:  B N Cohen; E D W Mackey; S R Grady; S McKinney; N E Patzlaff; C R Wageman; J M McIntosh; M J Marks; H A Lester; R M Drenan
Journal:  Neuroscience       Date:  2011-11-04       Impact factor: 3.590

2.  Modulation of gain-of-function α6*-nicotinic acetylcholine receptor by β3 subunits.

Authors:  Bhagirathi Dash; Ronald J Lukas
Journal:  J Biol Chem       Date:  2012-02-07       Impact factor: 5.157

Review 3.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

4.  Expression of functional human α6β2β3* acetylcholine receptors in Xenopus laevis oocytes achieved through subunit chimeras and concatamers.

Authors:  Alexandre Kuryatov; Jon Lindstrom
Journal:  Mol Pharmacol       Date:  2010-10-05       Impact factor: 4.436

5.  Behavioral effects of psychostimulants in mutant mice with cell-type specific deletion of CB2 cannabinoid receptors in dopamine neurons.

Authors:  Ana Canseco-Alba; Norman Schanz; Branden Sanabria; Juan Zhao; Zhicheng Lin; Qing-Rong Liu; Emmanuel S Onaivi
Journal:  Behav Brain Res       Date:  2018-11-30       Impact factor: 3.332

6.  Mesolimbic dopamine and habenulo-interpeduncular pathways in nicotine withdrawal.

Authors:  John A Dani; Mariella De Biasi
Journal:  Cold Spring Harb Perspect Med       Date:  2013-06-01       Impact factor: 6.915

7.  Elucidation of molecular impediments in the α6 subunit for in vitro expression of functional α6β4* nicotinic acetylcholine receptors.

Authors:  Anne B Jensen; Kirsten Hoestgaard-Jensen; Anders A Jensen
Journal:  J Biol Chem       Date:  2013-10-01       Impact factor: 5.157

8.  Nicotine and ethanol cooperate to enhance ventral tegmental area AMPA receptor function via α6-containing nicotinic receptors.

Authors:  Staci E Engle; J Michael McIntosh; Ryan M Drenan
Journal:  Neuropharmacology       Date:  2014-12-04       Impact factor: 5.250

9.  Amphetamine enantiomers inhibit homomeric α7 nicotinic receptor through a competitive mechanism and within the intoxication levels in humans.

Authors:  Daniel R Garton; Sharmaine G Ross; Rafael Maldonado-Hernández; Matthias Quick; José A Lasalde-Dominicci; José E Lizardi-Ortiz
Journal:  Neuropharmacology       Date:  2018-10-23       Impact factor: 5.250

10.  α6 subunit-containing nicotinic receptors mediate low-dose ethanol effects on ventral tegmental area neurons and ethanol reward.

Authors:  Scott C Steffensen; Samuel I Shin; Ashley C Nelson; Stephanie S Pistorius; Stephanie B Williams; Taylor J Woodward; Hyun Jung Park; Lindsey Friend; Ming Gao; Fenfei Gao; Devin H Taylor; M Foster Olive; Jeffrey G Edwards; Sterling N Sudweeks; Lori M Buhlman; J Michael McIntosh; Jie Wu
Journal:  Addict Biol       Date:  2017-09-13       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.